Reviewing Regulus Therapeutics (NASDAQ:RGLS) and Endonovo Therapeutics (OTCMKTS:ENDVD)

Regulus Therapeutics (NASDAQ:RGLS) and Endonovo Therapeutics (OTCMKTS:ENDVD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Earnings and Valuation

This table compares Regulus Therapeutics and Endonovo Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regulus Therapeutics	N/A	N/A	-$30.04 million	($1.07)	-1.48
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	N/A	N/A

Endonovo Therapeutics has higher revenue and earnings than Regulus Therapeutics.

Profitability

This table compares Regulus Therapeutics and Endonovo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regulus Therapeutics	N/A	-53.07%	-48.58%
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Regulus Therapeutics and Endonovo Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regulus Therapeutics	0	1	5	0	2.83
Endonovo Therapeutics	0	0	0	0	0.00

Regulus Therapeutics presently has a consensus target price of $10.80, indicating a potential upside of 583.54%. Given Regulus Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Regulus Therapeutics is more favorable than Endonovo Therapeutics.

Volatility & Risk

Regulus Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500.

Insider & Institutional Ownership

92.4% of Regulus Therapeutics shares are owned by institutional investors. 4.4% of Regulus Therapeutics shares are owned by insiders. Comparatively, 5.6% of Endonovo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Regulus Therapeutics beats Endonovo Therapeutics on 6 of the 11 factors compared between the two stocks.

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.